Introduction: Both heroin use and depression are significant health problems. Methadone maintenance treatment (MMT) can be of great benefit to heroin users. However, changes in the level of depression in heroin users during MMT are not clear. Gender and age are also important factors in the development of depression, and whether gender and age moderate changes in depression in heroin users during MMT warrants further study. This study aimed to explore: (1) the trajectory of depression in opioid users during MMT and (2) the moderating effects of gender and age on the trajectory of depression in opioid users receiving MMT.

Method: A total of 294 intravenous heroin users were recruited into this 9-month observational study. The level of depression was measured at the intake interview and at follow-up interviews every 3 months. A latent growth model was used to analyze the trajectory of the level of depression among the participants.

Results: Depression improved rapidly during the first 3 months of MMT and slowly after the first 3 months in both the female and male heroin users. There was no gender difference in the level of depression at each follow-up point. The level of depression in the female heroin users decreased faster than that in the male heroin users. In addition, the level of depression in the younger heroin users decreased faster than that in the older subjects.

Conclusion: Depression in female and younger heroin users improved more rapidly than in male and older subjects, respectively.

Keywords: opioid, methadone, depression, trajectory, gender, age, addiction

INTRODUCTION

Heroin dependence has many negative effects, such as inadvertent overdose, increased risk of infection, unemployment, social cost due to criminal activities, and family disruption (1). Around 0.7% of adults worldwide use opioids, the most common of which is heroin (2). Therefore, heroin use disorder is an important health issue.
Depression is a commonly occurring, serious, recurrent disorder linked to diminished role function and quality of life, medical morbidity, and mortality (3). Depression was ranked the fourth leading cause of disability worldwide by the World Health Organization and is expected to be the second leading cause in 2020 (4). In addition, a previous study demonstrated that substance use disorder is positively associated with depression (5). The prevalence of depression among heroin users is high, ranging between 20 and 45% (6, 7). Furthermore, heroin users with depression may be associated with greater drug use and risky behavior (6). Therefore, depression is an important mental issue in opioid users.

Methadone maintenance treatment (MMT), an opioid agonist, has been used to treat heroin users for heroin dependence since the mid-1960s (8). MMT contributes to decreases in drug use, drug-injecting behaviors, drug-related criminal behaviors, unprotected sexual behaviors, human immunodeficiency virus infections, and overdose deaths, and improves psychiatric comorbidity (9–12). Previous studies have indicated that the rate of current major depression declined by 15% during 12-month MMT, and the rate of clinically significant depression decreased by 30% during 18-month MMT (6, 13). In the general population, the trajectory of the course of depressive symptoms is quite heterogeneous, which is important for depression treatment (14); however, the trajectory of the decline in the level of depression during MMT is not clear, and is an important question in patients with MMT.

Depression is more prevalent among women than men, the male to female ratio being approximately 1:2 (15). A study of alcohol users found that female alcohol users had a higher level of depression than males (16). Regarding heroin users, women may be more likely than men to suffer from all kinds of mental illness (17). Both studies supported the idea that female heroin users may suffer more depressive problems than male heroin users, regardless of age. Furthermore, a study indicated that depression was more prevalent among female than male regular heroin users (18). All these results indicated that gender is important in relation to heroin users’ mental health, especially depression. Therefore, the way in which gender moderates change in the level of depression in opioid users undergoing MMT is an important issue.

In the general population, age plays an important role in the severity of depression, the level of depression increasing with age (19). In opioid users, cross-sectional study showed that age is a risk factor for depression (7). Therefore, the way in which age moderates the trajectory of depression is important for clinicians. Latent growth curve modeling (LGM) is an application of a structure equation model (SEM) used to analyze the change of repeated measures of a variable (20). One of the advantages of LGM is the ability to model aspects of change, and not only to describe a single individual trajectory, but also to capture individual differences in trajectories over time. Another advantage of LGM is its flexibility in allowing researchers to fully examine the questions that they propose. In this study, LGM was used to study the trajectory of the level of depression in heroin users undergoing MMT. The aims of the present study were to explore: (1) the trajectory of depression in opioid users during 9-month MMT and (2) the moderating effects of gender and age on the trajectory of depression in opioid users receiving MMT.

**MATERIALS AND METHODS**

**Research Design and Participants**

This 9-month prospective observational study, conducted from August 2013 to July 2015, recruited consecutive intravenous heroin users with heroin dependence according to the criteria of the DSM-IV-TR (21). All participants were referred by their doctor when they visited outpatient methadone clinics of three hospitals (two general hospitals and one psychiatric hospital) in southern Taiwan. Psychiatrists used the Mini International Neuropsychiatry Interview to determine participants’ psychopathologies. Mental state was determined from each participant’s past history. Those who had severe psychopathologies such as schizophrenia, bipolar disorder, or major depressive disorder, mental retardation, or those who had severe heroin withdrawal symptoms that might inhibit their ability to comprehend the procedure and questionnaires, were excluded. Three-hundred sixty patients were screened, and 66 refused to participate. A total of 294 intravenous heroin users agreed to participate and completed this study. None of the participants had received MMT before the interview at intake or took any psychotropic drugs during the study. During the 9-month follow-up period, participants were re-evaluated by research assistants, blind to the baseline data, every 3 months. The protocol was approved by the Institutional Review Board of Kaohsiung Medical University. Written informed consent was obtained from all participants prior to entry into the study. All participants received 10 USD for compensation when they completed the study.

**Survey Instruments**

The participants underwent interviews at intake to collect baseline data, including age, sex, and level of depression, before receiving MMT. At the follow-up interviews, the level of depression as measured using the Taiwanese version of the Center for Epidemiological Studies Depression Scale (CES-D), and the mean dosage of methadone during the past 3 months was recorded. The Taiwanese version of the CES-D has been used for the study of depression in Taiwan for many years (22). Cronbach’s alpha for the CES-D was 0.875. The total score on the CES-D ranged from 0 to 60, with higher scores indicating more severe depressive symptoms. Meanwhile, we determined a total score of 15 to be the cutoff point for clinically significant depression based on previous studies (13, 22).

**Data Collection Procedures and Statistical Analysis**

Data analysis was performed using SPSS 17.0 software (SPSS, Chicago, IL, USA). We used descriptive statistics, including means and SDs, to describe socio-demographic data, methadone dosage, and level of depression. Baseline characteristics were compared between the male and female heroin users using Student’s t-test. ANCOVA was used to examine the gender differences in the level of depression and dosage of methadone, controlling age, and education. Cohen’s d was used to calculate effect sizes. To
examine the difference in the level of depression between intake and each follow-up point, paired t-tests with adjusted multiple comparisons were used. Then, we performed LGM in the SEM using Analysis of Moment Structures to explore how the level of depression changed in the heroin users during the course of the MMT program. The hypothesized model was as shown in Figure 1. The indices used for estimating the goodness of fit of the model were the χ² goodness of fit value (p-value) > 0.05, the comparison of fit index (CFI) > 0.9, and the root mean square error of approximation (RMSEA) < 0.1. We made inferences at the 0.05 level of significance for all inferential statistical procedures.

**RESULTS**

The epidemiological characteristics, level of depression, and dosage of methadone at each hospital are shown in Table 1. These data did not differ significantly among the three hospitals. The level of depression and dosage of methadone at each follow-up point are shown in Table 2. The mean of the level of depression at intake was significantly higher than a CES-D score of 15 (t = 8.44, p < 0.001), indicating a clinically significant level of depression. The level of depression after 3, 6, and 9 months was significantly lower than that at intake (paired t = 8.61, 8.66, and 9.76, respectively, p < 0.001 for all three). There was no significant difference in the level of depression at the end of 3, 6, and 9 months (paired t = 0.58, 1.13, and 1.79, respectively, p = 0.561, 0.222, and 0.061, respectively). There was no significant difference in the dosage of methadone between the first, second, and third 3-month periods (paired t = −1.11, 1.39, and 0.55, respectively, p = 0.267, 0.165, and 0.583, respectively).

The mean age of the male and female heroin users was 39.62 (SD = 7.45) and 35.15 years (SD = 7.89), respectively. The

![Figure 1](image-url) | Latent growth model of the level of depression in heroin users undergoing methadone maintenance treatment.
gender difference for age was significant ($t = −3.390$, $p = 0.001$). Compared with the level of depression at intake, the male heroin users showed significant decreases at the end of 3, 6, and 9 months (paired $t = 7.48$, 7.37, and 8.45, respectively, $p < 0.001$, <0.001, and <0.001, respectively). However, the level of depression of the male heroin users after 3 months did not differ from that after 6 months (paired $t = 0.67$, $p = 0.501$), and the difference in the level of depression between the end of the 6- and 9-month periods was not significant (paired $t = 1.35$, $p = 0.179$). The methadone dosage of the male heroin users also did not differ significantly between the first, second, and third 3-month periods (paired $t = −1.57$, $−0.13$, and 1.04, respectively, $p = 0.119$, 0.898, and 0.299, respectively). Furthermore, the female heroin users also exhibited a significantly lower level of depression at the 3-, 6-, and 9-month follow-up points than at intake (paired $t = 4.55$, 4.93, and 5.33, respectively, all $p < 0.001$). No significant difference in the level of depression was found between the 3-, 6-, and 9-month follow-up points in the female heroin users (paired $t = −0.21$, $−0.46$, and $−0.24$, respectively, $p = 0.835$, 0.647, and 0.614, respectively). Meanwhile, the methadone dosage of the female heroin users did not change significantly between the first, second, and third 3-month periods (paired $t = 0.77$, 1.43, and 0.99, respectively, $p = 0.449$, 0.161, and 0.330, respectively).

The latent growth model is shown in Figure 2. The $\chi^2$ goodness-of-fit value ($p$-value) was 0.133, the CFI was 0.994, and the RMSEA was 0.033. All these indices showed that the latent growth model was of a good fit. The estimated mean of the slope (SLOPE) was $−17.124$ ($p < 0.001$), indicating that the level of depression decreased after starting MMT. Taking the total improvement in the level of depression during the 9-month treatment duration as a whole, an 86% improvement was observed during the first 3 months of MMT, as indicated by a regression weight between the slope and the first 3-month follow-up point during MMT, the regression weight between the slope and the second 3-month follow-up point during MMT, the regression weight between the slope and the second 3-month follow-up point during MMT, and the third 3-month follow-up point during MMT, respectively. No significant difference in the level of depression being 0.91. Meanwhile, the estimated mean of the intercept (ICEPT) was 28.873 ($p < 0.001$), and furthermore, the variances of the SLOPE and ICEPT were significant ($p < 0.001$).

The female heroin users had a higher level of depression at intake than the male heroin users, the regression weight from gender to ICEPT being significant and negative (coeff = $−7.941$, $p < 0.001$). In contrast, the level of depression of the female heroin users reduced more rapidly than that of the male heroin users, the regression weight from gender to SLOPE being significantly positive, which resulted in a less negative slope (coeff = 4.236, 1.35, 0.24, respectively, $p = 0.001$, <0.001, and <0.001, respectively). Hence, the relationship between gender and depression was positive in the female heroin users and negative in the male heroin users. This finding implies that female heroin users benefit more from MMT than male heroin users. The difference in the level of depression being 0.91. Meanwhile, the estimated mean of the intercept (ICEPT) was 28.873 ($p < 0.001$), and furthermore, the variances of the SLOPE and ICEPT were significant ($p < 0.001$).

The female heroin users had a higher level of depression at intake than the male heroin users, the regression weight from gender to ICEPT being significant and negative (coeff = $−7.941$, $p < 0.001$). In contrast, the level of depression of the female heroin users reduced more rapidly than that of the male heroin users, the regression weight from gender to SLOPE being significantly positive, which resulted in a less negative slope (coeff = 4.236, 1.35, 0.24, respectively, $p = 0.001$, <0.001, and <0.001, respectively). Hence, the relationship between gender and depression was positive in the female heroin users and negative in the male heroin users. This finding implies that female heroin users benefit more from MMT than male heroin users.

### TABLE 1 | Epidemiology, level of depression, and dosage of methadone among the three hospitals.

|                  | Male participants, mean (SD) | Female participants, mean (SD) |
|------------------|------------------------------|-------------------------------|
|                  | (n = 294)                    | (n = 37)                      |
| At intake        | 21.76 (15.54)                | 28.83 (11.74)                 |
| At end of the first 3 months | 20.91 (11.29)                | 18.43 (10.53)                 |
| At end of the second 3 months | 16.00 (10.12)                | 15.60 (10.91)                 |
| At end of the third 3 months | 15.34 (10.75)                | 14.82 (10.67)                 |
| At intake        | 21.76 (11.54)                | 22.61 (12.43)                 |
| At end of the first 3 months | 20.91 (11.29)                | 21.68 (10.34)                 |
| At end of the second 3 months | 16.00 (10.12)                | 15.69 (10.90)                 |
| At end of the third 3 months | 15.34 (10.75)                | 14.86 (10.67)                 |
| Age (years)      | 38.3 (7.63)                  | 39.63 (7.63)                  |
| Education (years) | 9.78 (1.95)                  | 9.74 (2.54)                   |
| Gender (male)    | 64 (92.75)                   | 132 (84.62)                   |

**Table 1**: Epidemiology, level of depression, and dosage of methadone at each follow-up point for heroin users.

|                      | Male participants, mean (SD) | Female participants, mean (SD) |
|----------------------|-----------------------------|--------------------------------|
|                      | (n = 257)                   | (n = 37)                       |
| Age (years)          | 38.3 (7.63)                 | 39.63 (7.63)                   |
| Education (years)    | 9.78 (1.95)                 | 9.74 (2.54)                    |
| Gender (male)        | 64 (92.75)                  | 132 (84.62)                    |

### TABLE 2 | Level of depression and dosage of methadone at each follow-up point for heroin users.

|                      | Total participants, mean (SD) | Male participants, mean (SD) | Female participants, mean (SD) |
|----------------------|-----------------------------|------------------------------|--------------------------------|
|                      | (n = 294)                   | (n = 257)                    | (n = 37)                       |
| At intake            | 21.76 (15.54)               | 20.91 (11.29)                | 28.83 (11.74)                  |
| At end of the first 3 months | 16.00 (10.12)                | 15.60 (10.91)                | 18.54 (11.07)                  |
| At end of the second 3 months | 15.34 (10.75)               | 14.82 (10.67)                | 18.62 (9.69)                   |
| At end of the third 3 months | 55.99 (28.73)                | 55.95 (28.84)                | 56.22 (28.34)                  |

**Table 2**: Epidemiology, level of depression, and dosage of methadone at each follow-up point for heroin users.

$\chi^2$ test for categorical variables; ANOVA for other variables.

* $p$-Value is less than 0.001.

* $p$-Value is less than 0.001.

* Cohen’s $d$.

* Controlling age and education.
In addition, the level of depression of the younger heroin users decreased faster than that of the older heroin users, age having a significantly positive regression weight on SLOPE (coeff = 0.178, p = 0.033). However, age did not have a significant effect on ICEPT (coeff = -0.001, p = 0.992). The methadone dosage did not have a significant effect on the change in the level of depression (coeff = -0.034, p = 0.064).

**DISCUSSION**

There were several interesting findings in this study. The first important finding was that the heroin users had a markedly high level of depression before starting MMT, the average CES-D score being higher than 15, with a previous study recommending that a total CES-D score of 15 or higher indicates the presence of clinically significant depression (22). Depression is a common comorbidity in people with substance use disorder (23). Furthermore, heroin users may have a higher level of depression than that of the general population, with up to one-quarter of users meeting the criteria for major depression (24). A previous study indicated that heroin users may have different prevalence rates of major depressive disorder at the initiation of different treatment modalities (7). Our results were in line with those of previous studies. Furthermore, this study showed that there were individual differences in the level of depression in patients undergoing the same treatment modality, as indicated by the statistically significant variance of the intercept. Previous studies have shown that depression is a high-risk factor for suicide among heroin users (25, 26). The findings of the present and previous studies indicated that depression is an important mental health issue for
We also observed a positive significant effect of age on the change in the level of depression. Compared with the younger heroin users, the older heroin users had a slower rate of decrease in the level of depression. In addition, age is a risk factor for depression (19, 31). Therefore, clinicians may need to pay more attention to the issue of depression when treating older heroin users.

There were several limitations of this study. First, although the present study was a prospective observational study, the causality between depression and MMT still could not be exactly determined. In addition, we surveyed the severity of depression using self-reported instruments, and did not make clinical diagnoses using standard diagnostic interviewing procedures. Finally, it should be noted that this was a sample of active treatment seekers, all of whom underwent MMT for 9 months.

CONCLUSION

This study demonstrated that female and male heroin users had a similar trajectory of the level of depression, most of the improvement being observed to have developed during the first 3 months of treatment, with only minimal improvement being seen beyond the 3-month point. Meanwhile, the severity of depression of the female heroin users improved more rapidly than that of the male heroin users. Irrespective of the improvement in the level of depression, the heroin users had a high incidence of depression at intake of MMT. Regular screening for depression in heroin users is warranted to ensure early identification of those with depression.

ETHICS STATEMENT

The protocol was approved by the Institutional Review Board of Kaohsiung Medical University.

AUTHOR CONTRIBUTIONS

P-WW drafted the work; H-CL and Y-HY collected data; C-YH, K-SC, and H-CW analyzed the data; and CFY designed this study.

ACKNOWLEDGMENTS

This study was supported by grants (KMUH-105-5R-58 and KMUH 105-5T-04) awarded to Kaohsiung Medical University Hospital. All authors have no relevant financial or non-financial relationships to disclose.

REFERENCES

1. Brown R. Heroin dependence. WMJ (2004) 103:20–6.
2. United Nations Office on Drugs and Crime. World Drug Report 2015. United Nations Publications, Sales No. E.15.XI.6 (2015). Available from: http://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf
3. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry (2004) 184:386–92. doi:10.1192/bjp.184.5.386
4. Murray CJ, Lopez AD. Evidence-based health policy—lessons from the global burden of disease study. Science (1996) 274:740–3. doi:10.1126/science.274.5288.740
5. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry (2004) 61:807–16. doi:10.1001/archpsyc.61.8.807
6. Havard A, Teesson M, Darke S, Ross J. Depression among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). J Subst Abuse Treat (2006) 30:355–62. doi:10.1016/j.jsat.2006.03.012
7. Teesson M, Havard A, Fairbairn S, Ross J, Lynskey M, Darke S. Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking. Drug Alcohol Depend (2005) 78:309–15. doi:10.1016/j.drugalcdep.2004.12.001
8. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA (1965) 193:646–50. doi:10.1001/jama.1965.03090080008002
9. Gowling LR, Farrell M, Bornemann R, Sullivan LE, Ali RL. Brief report: methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med (2006) 21:193–5. doi:10.1007/s11606-006-0258-x
10. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction (1998) 93:515–32. doi:10.1046/j.1520-5136.1998.9345157.x
11. Pani PP, Maremmani I, Pacini M, Lamanna F, Maremmani AG, DelRosso L. Effect of psychiatric severity on the outcome of methadone maintenance treatment. Eur Addict Res (2011) 17:80–9. doi:10.1159/000321465
12. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M; Amsterdam Cohort. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (2007) 102:1454–62. doi:10.1111/j.1360-0443.2007.01912.x
13. Zhang J, Sun W, Kong Y, Wang C. Reliability and validity of the Center for Epidemiological Studies Depression Scale in 2 special adult samples from rural China. Compr Psychiatry (2012) 53:1243–51. doi:10.1016/j.comppsych.2012.03.015
14. Chin WY, Choi EPH, Wan EYF. Trajectory pathways for depressive symptoms and their associated factors in a Chinese primary care cohort by growth mixture modelling. PLoS One (2011) 611:e0147775. doi:10.1371/journal.pone.0147775
15. Kessler RC. Epidemiology of women and depression. J Affect Disord (2003) 74:5–13. doi:10.1016/S0165-0327(02)00426-3
16. Abulseoud OA, Karpyak VM, Schneekloth T, Hall-Flavin DK, Loukianova LL, Geske JR, et al. A retrospective study of gender differences in depressive symptoms and risk of relapse in patients with alcohol dependence. Am J Addict (2013) 22:437–42. doi:10.1111/j.1521-0391.2013.12021.x
17. Shand FL, Degenhardt L, Slade T, Nelson EC. Sex differences amongst drug users. Addiction (2017) 112:154–62. doi:10.1111/add.14272
18. Sordo L, Chahua M, Bravo MJ, Barrio G, Brugal MT, Domingo-Salvany A, et al. Depression among regular heroin users: the influence of gender. Addict Behav (2012) 37:148–52. doi:10.1016/j.addbeh.2011.09.009
19. Stordal E, Myklebut A, Dahl AA. The association between age and depression in the general population: a multivariate examination. Acta Psychiatr Scand (2003) 107:132–41. doi:10.1034/j.1600-0447.2003.02056.x
20. Duncan TE, Duncan SC. The ABC’s of LGM: an introductory guide to latent variable growth curve modeling. Soc Personal Psychol Compass (2009) 3:979–91. doi:10.1111/j.1751-9044.2009.00224.x
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press, American Psychiatric Association (2000).
22. Chien CP, Cheng TA. Depression in Taiwan: epidemiological survey utilizing CES-D. Seishin Shinkeigaku Zasshi (1985) 87:335–8.
23. Bromore BK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry (1997) 54:71–80. doi:10.1001/archpsyc.1997.01830130077015
24. Darke S, Mills K, Teesson M, Ross J, Williamson A, Havard A. Patterns of major depression and drug-related problems amongst heroin users across 36 months. Psychiatry Res (2009) 1667–14. doi:10.1016/j.psychres.2007.12.007
25. Darke S, Williamson A, Ross J, Teesson M. Attempted suicide among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend (2005) 78:177–86. doi:10.1016/j.drugalcdep.2004.10.009
26. Darke S, Ross J, Williamson A, Mills KL, Havard A, Teesson M. Patterns and correlates of attempted suicide by heroin users over a 3-year period: findings from the Australian treatment outcome study. Drug Alcohol Depend (2007) 87:146–52. doi:10.1016/j.drugalcdep.2006.08.010
27. Scheibe S, Preuschhof C, Cristi C, Bagby RM. Are there gender differences in major depression and its response to antidepressants? J Affect Disord (2003) 75:223–35. doi:10.1016/S0165-0327(02)00050-2
28. Maremmani I, Pacini M, Pani PP, Perugi G, Deltito J, Akiskal H. The mental status of 1990 heroin addicts at entry into treatment: should depression be considered a ‘dual diagnosis’. Ann Gen Psychiatry (2007) 6:31. doi:10.1186/1744-859X-6-31
29. Kosten TR, Rounsaville BJ, Kleber HD. Relationship of depression to psychosocial stressors in heroin addicts. J Nerv Ment Dis (1983) 171:97–104. doi:10.1097/00005053-198302000-00006
30. Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, et al. Short-term outcomes for the treatment of heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addict Disord Their Treat (2006) 5:13–43. doi:10.1097/01.add.0000210717.33564.a8
31. Stordal E, Bjartveit Krüger M, Dahl NH, Krüger Ø, Myklebut A, Dahl AA. Depression in relation to age and gender in the general population: the Nord-Trondelag Health Study (HUNT). Acta Psychiatr Scand (2001) 104:210–6. doi:10.1034/j.1600-0447.2001.00130.x

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Wang, Lin, Yang, Hsu, Chung, Wu and Yen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided that the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.